Geneva, Switzerland and Boston, MA - August 10, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that the company management will participate in the Wedbush PacGrow Healthcare Conference taking place on August 14-15, 2018, in New York City.
ObsEva's presentation will take place on Tuesday, August 14th, 2018, at 8:00 a.m. Eastern Time (ET). A webcast will be available in the "Investors" section of ObsEva's website www.ObsEva.com.
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV", as well as the SIX Swiss Exchange where it is trading under the ticker symbol "OBSN".
For more information, please visit www.ObsEva.com.
For further information, please contact:
Media Contact Switzerland and Europe:Christophe LampsDynamics Groupcla@dynamicsgroup.ch +41 22 308 6220 Office+41 79 476 26 87 Mobile
Media Contact U.S.:Jeanene TimberlakeRooneyPartners LLCjtimberlake@rooneyco.com+1 646 770 8858
CEO Office Contact:Shauna Dillonshauna.firstname.lastname@example.org+41 22 552 1550
Investor Contact:Mario CorsoSenior Director, Investor Relationsmario.email@example.com+1 857 972 9347 Office+1 781 366 5726 Mobile
Press ReleaseThis announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.Source: ObsEva SA via Globenewswire --- End of Message --- ObsEva SAChemin des Aulx; 12 Plan-les-Ouates Switzerland